Back to resultsCopy Number Variation in CHRNA7 Gene in Migraine and Gene Expression
Primary Purpose
Migraine
Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Migraine CNV
Sponsored by
About this trial
This is an interventional basic science trial for Migraine
Eligibility Criteria
Inclusion Criteria:
Migraine
Exclusion Criteria:
Vascular problems
Sites / Locations
- Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Experimental
Arm Label
Case-Control
Case-Control 1
Arm Description
Copy number variation
Gene expression
Outcomes
Primary Outcome Measures
CNV number
CNV number effect on migraine
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04912752
Brief Title
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression
Official Title
Copy Number Variation in Migraine and Gene Expression
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
April 5, 2020 (Actual)
Primary Completion Date
December 10, 2020 (Actual)
Study Completion Date
January 2, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Gaziantep
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Migraine is a common and possible hereditary disease. Copy number variation (CNV) is a phenomenon in which parts of the genome are repeated and the number of repeats in the genome varies between individuals in the human population.The CHRNA7 gene has a major role in the neuropsychiatric phenotypes observed in patients. The 15q13.3 gain/loss variation in this gene may be associated with migraine.
Detailed Description
Migraine is a common neurological disorder. Although they have different genetic bases according to their types, cholinergic receptors after calcium channels play an important role in the clinic and genetics of the disease. Neuronal acetylcholine receptor subunit alpha-7, also known as nAChRα7, is a protein that in humans is encoded by the CHRNA7 gene.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Case-Control
Arm Type
Other
Arm Description
Copy number variation
Arm Title
Case-Control 1
Arm Type
Experimental
Arm Description
Gene expression
Intervention Type
Genetic
Intervention Name(s)
Migraine CNV
Intervention Description
Copy number variation effect on migraine disease
Primary Outcome Measure Information:
Title
CNV number
Description
CNV number effect on migraine
Time Frame
1 year
10. Eligibility
Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Migraine
Exclusion Criteria:
Vascular problems
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mehmet Fatih Özaltun, MD
Organizational Affiliation
Assist
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medicine
City
Gaziantep
State/Province
Şehitkamil
ZIP/Postal Code
27310
Country
Turkey
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
manuscript not yet published
Learn more about this trial
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression
We'll reach out to this number within 24 hrs